A PhaseⅠb Study Evaluating Safety and Efficacy of C-CAR011 Treatment in B- NHL Subjects
This is a single arm, single-center, non-randomized study to evaluate the safety and efficacy of C-CAR011 therapy in relapsed or refractory B cell Non-Hodgkin Lymphoma (NHL).
B-cell Non-Hodgkin Lymphoma
BIOLOGICAL: CD19-directed CAR-T cells
AE, Incidence of adverse events (AEs) and serious adverse events (SAEs), 12 weeks
Overall response rate (ORR), The ORR will be assessed at weeks 4 ，weeks 12 ，months 6 and months 12, 12 months|Duration of remission (DOR), The DOR will be assessed at months 12, 12 months|Progression free survival (PFS), The PFS will be assessed at months 12, 12 months|Overall survival rate（OSR）, The OSR will be assessed at weeks 12 ，months 6 and months 12, 12 months
The study will include the following sequential phases: Screening, Pre- Treatment (Cell Product Preparation; Lymphodepleting Chemotherapy), Treatment and Follow-up